

MARKET REPORT



KOL Perspectives: BTK Inhibitors in RA

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



KOL Perspectives: BTK Inhibitors in RA

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

KOL Perspectives: BTK Inhibitors in RA

KOL Perspectives: BTK Inhibitors in RA

Summary

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics -

- Awareness and potential of BTK inhibitors in RA
- Perceptions of BMS-986142's Phase II trial design
- Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights

- Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data
- KOLs were divided over BMS-986142's ability to achieve ACR70 by Week 12 in a refractory patient population
- For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

- 5 Europe-based & 5 N. America-based
- Interviews performed during Q2 2018

KOL data is analyzed to produce -

- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Additional Details

Publisher : Global Data

Reference : GDHC058SP

Number of Pages : 26

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for KOL Perspectives: BTK Inhibitors in RA [Report Updated: 06-08-2018]

- Table of Contents Executive Summary Background Research Panel Composition Results & Implications Appendix

How to Buy...

KOL Perspectives: BTK Inhibitors in RA [Report Updated: 06-08-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/227765>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.